Clinical trial · Observational
Prospective Validation of a Points Score System Predicting 30-day Survival
Prospective Validation of a Points Score System Predicting 30-day Survival for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Point score prediction tool for 30-day survival | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Low-risk
- description
- Low-risk:score 0-6
- interventionNames
- Diagnostic Test: Point score prediction tool for 30-day survival
- label
- Intermediate-risk
- description
- Intermediate-risk: score 7-13
- interventionNames
- Diagnostic Test: Point score prediction tool for 30-day survival
- label
- High-risk
- description
- High-risk:score 14-20
- interventionNames
- Diagnostic Test: Point score prediction tool for 30-day survival
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 at time of consent 2. Ability to provide written informed consent 3. Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy 4. Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible 5. Those patients who undergo a course of palliative radiation therapy, it is not the requirement of this study to complete that course of treatment. Those who prematurely end their course of treatment will remain eligible Note: Patients who ultimately either choose to not receive radiation or not recommended to receive radiation will remain eligible Note: Patients who ultimately do not complete prescribed radiation will remain eligible Exclusion Criteria: 1. Patients who are unable to participate in follow up visits per investigator discretion (virtual/phone follow up is permitted) 2. Patients who are receiving definitive/curative course of radiation therapy 3. Patients who self-report as pregnant or nursing
References
Publications (0)
Data not yet available